Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Risk Management and Healthcare Policy
|
October 30, 2016
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies
Kelly F Bell, Arie Katz, John J Sheehan
Journal of Medical Economics
|
January 30, 2018
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar, et al.
American Health & Drug Benefits
|
August 11, 2017
Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas
Kelly F Bell, Katherine Cappell, Michael Liang, et al.
Expert Review of Endocrinology & Metabolism
|
February 13, 2019
Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data
Suellen Marie Curkendall, Bin Zhang, Gregory Lenhart, et al.
Archives of Public Health = Archives Belges De Sante Publique
|
March 1, 2014
The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data
Juliana L Meyers, Shreekant Parasuraman, Kelly F Bell, et al.
Current Medical Research and Opinion
|
July 3, 2013
Predictors of medication adherence in patients with type 2 diabetes mellitus
Suellen M Curkendall, Nina Thomas, Kelly F Bell, et al.
Journal of Medical Economics
|
January 28, 2017
Economic burden of comorbid chronic kidney disease and diabetes
R Brett McQueen, Sepehr Farahbakhshian, Kelly F Bell, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 2, 2014
Health care burden of dyspepsia among nonvalvular atrial fibrillation patients
Michael H Kim, Kelly F Bell, Dinara Makenbaeva, et al.
Current Medical Research and Opinion
|
October 26, 2016
Patient preferences for diabetes treatment attributes and drug classes
Emuella M Flood, Kelly F Bell, Marie C de la Cruz, et al.
The American Journal of Managed Care
|
April 26, 2018
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population
Eric T Wittbrodt, James M Eudicone, Kelly F Bell, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Risk Management and Healthcare Policy
|
October 30, 2016
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies
Kelly F Bell, Arie Katz, John J Sheehan
Journal of Medical Economics
|
January 30, 2018
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar, et al.
American Health & Drug Benefits
|
August 11, 2017
Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas
Kelly F Bell, Katherine Cappell, Michael Liang, et al.
Expert Review of Endocrinology & Metabolism
|
February 13, 2019
Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data
Suellen Marie Curkendall, Bin Zhang, Gregory Lenhart, et al.
Archives of Public Health = Archives Belges De Sante Publique
|
March 1, 2014
The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data
Juliana L Meyers, Shreekant Parasuraman, Kelly F Bell, et al.
Current Medical Research and Opinion
|
July 3, 2013
Predictors of medication adherence in patients with type 2 diabetes mellitus
Suellen M Curkendall, Nina Thomas, Kelly F Bell, et al.
Journal of Medical Economics
|
January 28, 2017
Economic burden of comorbid chronic kidney disease and diabetes
R Brett McQueen, Sepehr Farahbakhshian, Kelly F Bell, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 2, 2014
Health care burden of dyspepsia among nonvalvular atrial fibrillation patients
Michael H Kim, Kelly F Bell, Dinara Makenbaeva, et al.
Current Medical Research and Opinion
|
October 26, 2016
Patient preferences for diabetes treatment attributes and drug classes
Emuella M Flood, Kelly F Bell, Marie C de la Cruz, et al.
The American Journal of Managed Care
|
April 26, 2018
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population
Eric T Wittbrodt, James M Eudicone, Kelly F Bell, et al.
Page
of 2